

## SPECIALTY GUIDELINE MANAGEMENT

### leuprolide acetate injection

#### POLICY

#### I. INDICATIONS

The indications below including FDA-approved indications and compendial uses are considered a covered benefit provided that all the approval criteria are met and the member has no exclusions to the prescribed therapy.

##### A. FDA-Approved Indications

1. Prostate cancer: Leuprolide acetate is indicated in the palliative treatment of advanced prostate cancer.
2. Central precocious puberty (CPP): Leuprolide acetate is indicated in the treatment of children with central precocious puberty.

##### B. Compendial Uses

- A. Use as a stimulation test to confirm the diagnosis of CPP
- B. Use in combination with growth hormone for children with growth failure and advancing puberty
- C. Prostate cancer
  - a. Adjuvant therapy for lymph node-positive disease found during pelvic lymph node dissection (PLND)
  - b. Initial androgen deprivation therapy (ADT) for:
    - i. Intermediate risk group
    - ii. High or very high risk group
    - iii. Regional disease
    - iv. Metastatic disease
  - c. Recurrent disease in patients who experience biochemical failure after previous therapy
  - d. Progressive castration-naïve disease
- D. Inhibition of premature luteinizing hormone (LH) surges in women undergoing assisted reproductive technology

All other indications are considered experimental/investigational and are not a covered benefit.

#### II. EXCLUSIONS

Coverage will not be provided for members with prostate cancer if leuprolide acetate is used as neoadjuvant androgen deprivation therapy (ADT) for radical prostatectomy.

#### III. CRITERIA FOR INITIAL APPROVAL

##### A. **Central precocious puberty (CPP)**

1. Authorization up to age 12 may be granted for the treatment of CPP in a female member when all of the following criteria are met:
  - a. The diagnosis of CPP has been confirmed by a pubertal response to a gonadotropin releasing hormone (GnRH) agonist test or a pubertal level of a third generation luteinizing hormone (LH) assay
  - b. The diagnosis of CPP has been confirmed by assessment of bone age versus chronological age
  - c. The member was less than 8 years of age at the onset of secondary sexual characteristics
2. Authorization up to age 13 may be granted for the treatment of CPP in a male member when all of the following criteria are met:

- a. The diagnosis of CPP has been confirmed by a pubertal response to a GnRH agonist test or a pubertal level of a third generation LH assay
- b. The diagnosis of CPP has been confirmed by assessment of bone age versus chronological age
- c. The member was less than 9 years of age at the onset of secondary sexual characteristics

**B. Stimulation test for CPP diagnosis**

Authorization of one dose may be granted for use as a stimulation test to confirm the diagnosis of CPP.

**C. Advancing puberty and growth failure**

Authorization of 12 months may be granted for the treatment of advancing puberty and growth failure in a pediatric member when leuprolide acetate is used in combination with growth hormone.

**D. Prostate cancer**

1. Authorization of 12 months may be granted for treatment of lymph node-positive disease found during pelvic lymph node dissection (PLND) when leuprolide acetate is used as adjuvant therapy.
2. Authorization of 12 months may be granted for treatment of prostate cancer with intermediate, high or very high risk stratification when leuprolide acetate is used as initial androgen deprivation therapy (ADT).
3. Authorization of 12 months may be granted for treatment of regional or metastatic prostate cancer when leuprolide acetate is used as initial androgen deprivation therapy (ADT).
4. Authorization of 12 months may be granted for treatment of recurrent prostate cancer in members who experience biochemical failure after previous therapy.
5. Authorization of 12 months may be granted for treatment of progressive castration-naïve prostate cancer.

**E. Inhibition of premature LH surge<sup>‡</sup>**

1. Authorization of 12 months may be granted for the inhibition of LH surge in a member with infertility.

<sup>‡</sup> Specialty Guideline Management coverage review will be bypassed for leuprolide if it is being requested for a procedure that has been approved under a member's medical benefit plan. Such members will be exempt from the requirements in Section III E. A medical authorization number and confirmation of the approved procedure(s) will be required. *NOTE: Some plans may opt-out of medical benefit alignment. Members receiving coverage under such plans must meet the requirements in Section III E.*

**IV. CONTINUATION OF THERAPY**

**A. Central precocious puberty**

1. Authorization up to age 12 may be granted for continuation of therapy for CPP in a female member if the member is currently less than 12 years of age.
2. Authorization up to age 13 may be granted for continuation of therapy for CPP in a male member if the member is currently less than 13 years of age.

**B. Prostate cancer, stimulation test for CPP diagnosis, advancing puberty and growth failure, and infertility**

All members (including new members) requesting authorization for continuation of therapy must meet all initial authorization criteria.

**V. REFERENCES**

1. Leuprolide acetate injection [package insert]. Princeton, NJ: Sandoz Inc.; January 2017.
2. Leuprolide acetate injection for pediatric use [package insert]. Princeton, NJ: Sandoz Inc.; January 2017.
3. Micromedex Solutions [database online]. Ann Arbor, MI: Truven Health Analytics Inc. Updated periodically. [www.micromedexsolutions.com](http://www.micromedexsolutions.com) [available with subscription]. Accessed February 22, 2017.

4. Carel J, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics*. 2009;123:e752-e762.
5. Kletter GB, Klein KO, Wong YY. A pediatrician's guide to central precocious puberty. *Clin Pediatr*. 2015;54:414-424.
6. Houk CP, Kunselman AR, Lee PA. Adequacy of a single unstimulated luteinizing hormone level to diagnose central precocious puberty in girls. *Pediatrics*. 2009;123:e1059-e1063.
7. Kaplowitz P, Bloch C, the Section on Endocrinology. Evaluation and referral of children with signs of early puberty. *Pediatrics*. 2016;137:e20153732.
8. Kamp GA, Mul D, Waelkens JJ, et al. A randomized controlled trial of three years growth hormone and gonadotropin-releasing hormone agonist treatment in children with idiopathic short stature and intrauterine growth retardation. *J Clin Endocrinol Metab*. 2001;86:2969-2975.
9. Mericq V, Cajardo H, Effers M, et al. Effects of treatment with GH alone or in combination with LHRH analog on bone mineral density in pubertal GH-deficient patients. *J Clin Endocrinol Metab*. 2002;87:84-89.
10. Mul D, Wit JM, Oostdijk W, et al. The effect of pubertal delay by GnRH agonist in GH-deficient children on final height. *J Clin Endocrinol Metab*. 2001;86:4655-4656.
11. Quintos JB, Vogiatzi MG, Harbison MD, et al. Growth hormone therapy alone or in combination with gonadotropin-releasing hormone analog therapy to improve the height deficit in children with congenital adrenal hyperplasia. *J Clin Endocrinol Metab*. 2001;86:1511-1517.
12. Tanaka T, Satoh M, Yasunaga T, et al. GH and GnRH analog treatment in children who enter puberty at short stature. *J Pediatr Endocrinol Metab*. 1997;10:623-628.
13. The NCCN Drugs & Biologics Compendium® © 2016 National Comprehensive Cancer Network, Inc. <http://www.nccn.org>. Accessed November 09, 2016.
14. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer. Version 3.2016. [http://www.nccn.org/professionals/physician\\_gls/pdf/prostate.pdf](http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf). Accessed November 09, 2016.
15. Urman B, Yakin K. Ovulatory disorders and infertility. *J Reprod Med*. 2006;51(4):267-282.
16. National Collaborating Centre for Women's and Children's Health. Fertility: assessment and treatment for people with fertility problems (Clinical guideline no. 156). National Institute for Health and Clinical Excellence (NICE); 2013.